BioSpace News Archive

CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company’s Amended and Restated 2017 Equity Incentive Plan and material to the employees’ acceptance of employment with the company.

Iterum Therapeutics plc announced that two posters will be presented at the Infectious Disease Society of America’s IDWeek 2022.

InxMed Co., Ltd is pleased to announce that the clinical data from an open-label, phase Ib trial evaluating the efficacy and safety of IN10018, a highly potent and selective oral inhibitor of focal adhesion kinase, alone or in combination with cobimetinib in patients with Uveal Melanoma and NRAS-mutant melanoma.